?AI+Pharmaceutical? The value of the transformation and upgrading of China's pharmaceutical industry is huge, it will improve the efficiency of disease management and the quality of disease management, and will become a breakthrough in the future of big data + AI to promote the transformation of the pharmaceutical industry.

Domestic AI medical application companies started late, from the number of financing in the field of intelligent diagnostics accounted for 60% of the city, and overall intelligent diagnostics is still in the early stages, there is no large-scale commercial, for the extraction of high-quality medical data, the structuring and modeling of the data, the patient's language training, etc. are the current domestic efforts to improve the quality of medical data. Training and so on are all the current domestic focus on AI medical enterprises need to cross the barrier.

In the 21st century, clinical research evidence is the cornerstone of modern medical decision-making, and the application of big data-driven AI technology to clinical settings has become a future trend. For structured data decision-making, machine-assisted physician diagnosis and treatment in the next 5 ~ 10 years can bring obvious results; for unstructured medical problems, through the training of effective and real clinical datasets, based on mathematical algorithms model decision-making will replace the bias of human decision-making. Currently, big data-driven AI decision-making systems, whether used for prevention, diagnosis, treatment, or follow-up of disease management systems, have very significant barriers to application. The reason for this is not the level of technological sophistication, but rather the humanistic attributes of the medical discipline itself that characterize it.

Artificial Intelligence (AI) + healthcare is an innovative product formed by the integration of the medical and healthcare fields with information and communication technologies. At present, enterprises involved in the AI + medical field include several categories: first, the original medical device companies or medical service organizations take the initiative to embrace artificial intelligence and integrate with it; second, the Internet company cross-border into the field of AI + healthcare, Alibaba and Tencent have begun the layout in this regard; third, the startups that directly adopt the AI + healthcare model, the newly created companies directly into this Third, the direct adoption of AI + medical model startups, newly founded companies directly into this field, usually selected a niche or a consumer demand point of entry, such as the Hong Kong Stock Exchange-listed Ping An good doctor.